- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Cannell & Spears LLC Reduces Bristol Myers Squibb Holdings
Institutional investor cuts stake in pharmaceutical company by 6.7%
Mar. 15, 2026 at 10:36am
Got story updates? Submit your updates here. ›
Cannell & Spears LLC, an institutional investor, has reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 6.7% in the third quarter, according to a recent SEC filing. The firm now owns 252,914 shares of the biopharmaceutical company's stock, valued at $11.41 million.
Why it matters
This filing provides insight into the investment strategies of Cannell & Spears LLC and their view on the prospects of Bristol Myers Squibb, a major pharmaceutical company. Changes in institutional ownership can signal shifts in market sentiment around a stock.
The details
Cannell & Spears LLC sold 18,177 shares of Bristol Myers Squibb in the third quarter, reducing its total position to 252,914 shares. The firm's holdings in the company were valued at $11.41 million as of the most recent filing.
- Cannell & Spears LLC reduced its Bristol Myers Squibb holdings in the 3rd quarter of 2026.
The players
Cannell & Spears LLC
An institutional investor that manages a portfolio of investments, including shares in Bristol Myers Squibb.
Bristol Myers Squibb Company
A global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases.
The takeaway
This filing indicates that Cannell & Spears LLC has reduced its exposure to Bristol Myers Squibb, potentially signaling a shift in the firm's investment strategy or outlook on the pharmaceutical company's prospects. Investors may want to monitor any further changes in institutional ownership of Bristol Myers Squibb stock.
